Baird analyst Luke Junk maintains Amphenol (NYSE:APH) with a Outperform and raises the price target from $76 to $81.
Jazz Posts New Data for ALL/LBL Treatment At ASH 2021 Annual Meeting
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) revealed initial positive results from a Phase 2/3 trial of intramuscular (IM) administration of Rylaze (asparaginase erwinia…